pharmaand

specialty pharma / commercial-stage oncology products

Privately held: no public share price · Austria

Assets

(3 total)
3Total Assets
2Approved
0Phase 3 / Filed
1Phase 1–2 / Early
5Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
Type I interferon receptor
Chronic Hepatitis B
Approved
PARP (poly ADP-ribose polymerase) enzymes, PARP1/2Small molecule
Metastatic Castration-Resistant Prostate CancerOvarian CancerProstate Cancer
US approval withdrawn
HDACSmall molecule
Multiple Myeloma

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.